Negative Expression of DSG1 and DSG2, as Prognostic Biomarkers, Impacts on the Overall Survival in Patients with Extrahepatic Cholangiocarcinoma

Table 4

Correlations of clinicopathological characteristics, DSG1 and DSG2 expression with the mean survival in patients with EHCC.

Group	Number of patients ()	Median survival (month)	Log-rank
Sex
Male	61	12.67 (3-30)	0.001	0.980
Female	39	12.59 (4-30)
Age (year)
≤45	17	13.82 (3-30)	0.667	0.414
>45	83	12.10 (3-30)
Differentiation
Well	31	18.46 (5-30)
Moderately	34	11.41 (3-30)	27.655	0.000
Poorly	35	7.97 (3-30)
Tumor size
≤3 cm	62	12.62 (3-30)	0.235	0.628
>3 cm	38	12.03 (5-30)
TNM stage
I+II	35	18.57 (7-30)
III	38	11.05 (3-30)	57.569	0.000
IV	27	6.26 (3-13)
Lymph node metastasis
No	62	15.52 (4-30)	39.001	0.000
Yes	38	7.18 (3-25)
Invasion
No	33	17.52 (4-30)	17.399	0.000
Yes	67	9.87 (3-30)
Surgery
Radical	54	16.62 (3-30)	48.388	0.000
Palliative	36	7.58 (4-24)
Biopsy	10	6.90 (3-14)
DSG1
−	58	8.66 (3-30)	32.827	0.000
+	42	17.52 (6-30)
DSG2
−	53	8.40 (3-30)	31.002	0.000
+	47	16.89 (5-30)
DSG1 and DSG2
DSG1(-) DSG2(-)	41	8.087 (3-30)	39.007	0.000
DSG1(-) DSG2(+)	17	10.833 (5-18)
DSG1(+) DSG2(-)	17	10.429 (8-17)
DSG1(+) DSG2(+)	30	18.977 (6-30)

−: negative expression; +: positive expression.